<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00705432</url>
  </required_header>
  <id_info>
    <org_study_id>P05216</org_study_id>
    <secondary_id>EUDRACT # 2007-005508-42</secondary_id>
    <nct_id>NCT00705432</nct_id>
    <nct_alias>NCT00795431</nct_alias>
  </id_info>
  <brief_title>Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)</brief_title>
  <acronym>SPRINT-2</acronym>
  <official_title>A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves treatment with boceprevir or placebo in combination with PegIntron (PEG)
      + Ribavirin (RBV) (weight-based dosing [WBD]) in previously untreated adult participants with
      chronic hepatitis C (CHC) genotype 1. It is hypothesized that the addition of a third active
      anti- Hepatitis C Virus (anti-HCV) drug may lead to more rapid viral response than therapy
      with two drugs, and therefore, the addition of boceprevir to PegIntron plus ribavirin therapy
      after a 4-week lead-in period may allow for both increased rates of sustained virologic
      response (SVR) and shorter treatment durations (in some populations) than treatment with
      PegIntron plus ribavirin alone.

      The study includes two separate cohorts, Cohort I (White participants) and Cohort II (Black
      participants). Participants from each cohort are assigned (randomized) to one of three study
      arms, all of which have a 4-week lead-in period with (PEG + RBV).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants from Cohort I and Cohort II are assigned (randomized) to one of three study
      arms, all of which have a 4-week lead-in period with (PEG + RBV).

        1. Control arm, participants are treated with (PEG + RBV + placebo) for 44 weeks after the
           lead-in.

        2. Experimental arm with Response Guided Therapy (RGT)

           In this experimental arm, participants are treated with all three drugs (PEG + RBV +
           boceprevir) for 24 weeks after the lead-in. At treatment week 28, those participants
           with undetectable Hepatitis C Virus - ribonucleic acid (HCV-RNA) from week 8 (up to
           treatment week 24), will be considered to complete treatment, and will enter follow-up.
           Participants with detectable for HCV-RNA at week 8 or later will receive an additional
           20 weeks of therapy with PegIntron and Ribavirin (PEG + RBV + placebo).

        3. Experimental arm, participants are treated with all three drugs (PEG + RBV + Ribavirin)
           for 44 weeks after the lead-in.

      All participants were followed up to 72 weeks following randomization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virologic Response (SVR) Rate</measure>
    <time_frame>At Follow-up Week (FW) 24</time_frame>
    <description>Previously untreated adults with CHC genotype 1 were treated with the assigned study medication. Participants who had undetectable plasma HCV-RNA at FW 24 had achieved SVR. SVR rate is the percent of participants achieving SVR.
HCV-RNA was detected by a nucleic acid amplification test and the limit of detection for this assay is 9.3 IU/mL.
If a participant was missing data at FW 24 after having had undetectable HCV-RNA at FW 12, the participant was to be considered to have SVR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained Virologic Response (SVR) Rate in Participants Treated With Study Drug (Boceprevir or Placebo)</measure>
    <time_frame>At FW 24</time_frame>
    <description>Previously untreated adults with CHC genotype 1 were treated with the assigned study medication. Participants who had undetectable plasma HCV-RNA at FW 24 had achieved SVR. SVR rate was the percentage of participants treated with at least one dose of boceprevir or placebo who had achieved SVR.
HCV-RNA in participant's plasma samples was detected by a nucleic acid amplification assay with a limit of detection of 9.3 IU/mL.
If a participant was missing data at FW 24 after having had undetectable HCV-RNA at FW 12, the participant was to be considered to have a SVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Undetectable HCV-RNA at Follow-up Week 12 and at 72 Weeks After Randomization.</measure>
    <time_frame>At FW 12 and at 72 weeks after randomization</time_frame>
    <description>Previously untreated adults with CHC genotype 1 were treated with the assigned study medication. The number of participants who had undetectable plasma HCV-RNA at FW 12, and 72 weeks after randomization are reported.
HCV-RNA was detected by a nucleic acid amplification test and the limit of detection for this assay is 9.3 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Early Virologic Response (Undetectable HCV-RNA at Treatment Week 2, 4, 8, 12, 16, or 20)</measure>
    <time_frame>At Treatment Week 2, 4, 8, 12, 16, or 20</time_frame>
    <description>Early virologic response was defined as undetectable HCV-RNA at in participants by treatment week 2, 4, 8, 12, 16, or 20.
HCV-RNA in participant's plasma samples was detected by a nucleic acid amplification assay with a limit of detection of 9.3 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Early Virologic Response (Undetectable HCV-RNA at Treatment Week 4, 8, 12, 16, or 20) Who Achieved SVR</measure>
    <time_frame>At Treatment Week 4, 8, 12, 16, 20</time_frame>
    <description>Participants with early virologic response were those who had undetectable HCV-RNA by treatment week 4, 8, 12, 16, or 20. Participants who had undetectable plasma HCV-RNA at FW 24 had SVR. The number of participants with early virologic response that also achieved SVR is reported.
HCV-RNA in participant's plasma samples was detected by a nucleic acid amplification assay with a limit of detection of 9.3 IU/mL.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1472</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>1. Placebo + PEG + RBV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks (lead in treatment) followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Boceprevir + PEG + RBV - 24 Weeks (RGT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG 1.5 μg/kg + RBV (WBD) for 4 weeks (lead in treatment) followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.
At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable from Treatment Weeks 8 to Treatment Week 24, will proceed to the 44-week follow-up.
At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3. Boceprevir + PEG + RBV - 44 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG 1.5 μg/kg + RBV (WBD) for 4 weeks (lead in treatment) followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peginterferon alfa-2b (PEG)</intervention_name>
    <description>Peginterferon alfa-2b 1.5 μg/kg/week subcutaneously (SC)</description>
    <arm_group_label>1. Placebo + PEG + RBV</arm_group_label>
    <arm_group_label>2. Boceprevir + PEG + RBV - 24 Weeks (RGT)</arm_group_label>
    <arm_group_label>3. Boceprevir + PEG + RBV - 44 Weeks</arm_group_label>
    <other_name>PegIntron</other_name>
    <other_name>PEG</other_name>
    <other_name>SCH 54031</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day administered orally, divided twice daily (BID).</description>
    <arm_group_label>1. Placebo + PEG + RBV</arm_group_label>
    <arm_group_label>2. Boceprevir + PEG + RBV - 24 Weeks (RGT)</arm_group_label>
    <arm_group_label>3. Boceprevir + PEG + RBV - 44 Weeks</arm_group_label>
    <other_name>Rebetol</other_name>
    <other_name>RBV</other_name>
    <other_name>SCH 18908</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to boceprevir, 800 mg (4 x 200mg capsules) administered orally three times a day (TID).</description>
    <arm_group_label>1. Placebo + PEG + RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Boceprevir</intervention_name>
    <description>Boceprevir, 800 mg (4 x 200 mg capsules) administered orally TID.</description>
    <arm_group_label>2. Boceprevir + PEG + RBV - 24 Weeks (RGT)</arm_group_label>
    <arm_group_label>3. Boceprevir + PEG + RBV - 44 Weeks</arm_group_label>
    <other_name>SCH 503034, Victrelis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must have previously documented CHC genotype 1 infection.

          -  Participant must have a liver biopsy with histology consistent with CHC and no other
             etiology.

          -  Participants with bridging fibrosis or cirrhosis must have an ultrasound within 6
             months of the Screening Visit (or between Screening and Day 1) with no findings
             suspicious for hepatocellular carcinoma (HCC).

          -  Participant must be &gt;=18 years of age.

          -  Participant must weigh between 40 kg and 125 kg.

          -  Participant and participant's partner(s) must each agree to use acceptable methods of
             contraception for at least 2 weeks prior to Day 1 and continue until at least 6 months
             after last dose of study drug, or longer if dictated by local regulations.

          -  Participants must be willing to give written informed consent.

        Exclusion Criteria:

          -  Coinfection with the human immunodeficiency virus (HIV) or hepatitis B virus (HBsAg
             positive).

          -  Participants who received prior treatment for hepatitis C; other than herbal remedies,
             except those with known hepatotoxicity.

          -  Treatment with any investigational drug within 30 days of the randomization visit in
             this study.

          -  Participation in any other clinical trial within 30 days of randomization or intention
             to participate in another clinical trial during participation in this study.

          -  Evidence of decompensated liver disease including, but not limited to, a history or
             presence of clinical ascites, bleeding varices, or hepatic encephalopathy.

          -  Diabetic and/or hypertensive participants with clinically significant ocular
             examination findings: retinopathy, cotton wool spots, optic nerve disorder, retinal
             hemorrhage, or any other clinically significant abnormality.

          -  Pre-existing psychiatric condition(s).

          -  Clinical diagnosis of substance abuse of the specified drugs within the specified
             timeframes.

          -  Any known pre-existing medical condition that could interfere with the participant's
             participation in and completion of the study.

          -  Evidence of active or suspected malignancy, or a history of malignancy, within the
             last 5 years (except adequately treated carcinoma in situ and basal cell carcinoma of
             the skin). Participants under evaluation for malignancy are not eligible.

          -  Participants who are pregnant or nursing. Participants who intend to become pregnant
             during the study period. Male participants with partners who are, or intend to become,
             pregnant during the study period.

          -  Any other condition which, in the opinion of a physician, would make the participant
             unsuitable for enrollment or could interfere with the participant participating in and
             completing the study.

          -  Participants who are part of the site personnel directly involved with this study.

          -  Participants who are family members of the investigational study staff.

          -  Participants who had life-threatening serious adverse event (SAE) during screening
             period.

          -  Protocol-specified hematologic, biochemical, and serologic criteria: Hemoglobin &lt;12
             g/dL for females and &lt;13 g/dL for males; Neutrophils &lt;1500/mm^3 (blacks: &lt;1200/mm^3);
             Platelets &lt;100,000/mm^3; Direct bilirubin &gt;1.5 x upper limit of normal (ULN)

          -  Serum albumin &lt; lower limit of normal (LLN)

          -  Thyroid-stimulating hormone (TSH) &gt;1.2 x ULN or &lt;0.8 x LLN of laboratory, with certain
             exceptions.

          -  Serum creatinine &gt;ULN of the laboratory reference.

          -  Protocol-specified serum glucose concentrations.

          -  protocol-specified alpha fetoprotein levels.

          -  Prothrombin time/partial thromboplastin time (PT/PTT) values &gt;10% above laboratory
             reference range.

          -  Anti-nuclear antibodies (ANA) &gt;1:320.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2008</study_first_submitted>
  <study_first_submitted_qc>June 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2008</study_first_posted>
  <results_first_submitted>May 13, 2011</results_first_submitted>
  <results_first_submitted_qc>May 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 14, 2011</results_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>1472 participants were enrolled in this study.</recruitment_details>
      <pre_assignment_details>373 participants were screened but not randomized. 1099 participants were randomized. Only 1097 received at least one dose of PegIntron (PEG) + Ribavirin (RBV) (lead-in treatment).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort I - 1. Placebo + PEG + RBV</title>
          <description>Cohort I (White participants) treated with PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
        </group>
        <group group_id="P2">
          <title>Cohort I - 2. Boceprevir + PEG + RBV - 24 Weeks (RGT)</title>
          <description>Cohort I (White participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.
At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable at Treatment Week 8 and at all subsequent assays (up to Treatment Week 24), will proceed to the 44-week follow-up.
At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up.</description>
        </group>
        <group group_id="P3">
          <title>Cohort I - 3. Boceprevir + PEG + RBV - 44 Weeks</title>
          <description>Cohort I (White participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
        </group>
        <group group_id="P4">
          <title>Cohort II - 1. Placebo + PEG + RBV</title>
          <description>Cohort II (Black participants) treated with PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
        </group>
        <group group_id="P5">
          <title>Cohort II - 2. Boceprevir + PEG + RBV - 24 Weeks (RGT)</title>
          <description>Cohort II (Black participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.
At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable at Treatment Week 8 and at all subsequent assays (up to Treatment Week 24), will proceed to the 44-week follow-up.
At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up.</description>
        </group>
        <group group_id="P6">
          <title>Cohort II - 3. Boceprevir + PEG + RBV - 44 Weeks</title>
          <description>Cohort II (Black participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="311"/>
                <participants group_id="P2" count="316"/>
                <participants group_id="P3" count="311"/>
                <participants group_id="P4" count="52"/>
                <participants group_id="P5" count="52"/>
                <participants group_id="P6" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>STARTED BOCEPREVIR/PLACEBO</title>
              <participants_list>
                <participants group_id="P1" count="297"/>
                <participants group_id="P2" count="303"/>
                <participants group_id="P3" count="299"/>
                <participants group_id="P4" count="47"/>
                <participants group_id="P5" count="47"/>
                <participants group_id="P6" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="205"/>
                <participants group_id="P3" count="190"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="24"/>
                <participants group_id="P6" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="121"/>
                <participants group_id="P4" count="41"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment failure</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non medical reason</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up Period (Upto Week 72)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="278"/>
                <participants group_id="P2" count="295"/>
                <participants group_id="P3" count="291"/>
                <participants group_id="P4" count="42"/>
                <participants group_id="P5" count="44"/>
                <participants group_id="P6" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
                <participants group_id="P2" count="252"/>
                <participants group_id="P3" count="266"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="38"/>
                <participants group_id="P6" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non medical reason</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort I - 1. Placebo + PEG + RBV</title>
          <description>Cohort I (White participants) treated with PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
        </group>
        <group group_id="B2">
          <title>Cohort I - 2. Boceprevir + PEG + RBV - 24 Weeks (RGT)</title>
          <description>Cohort I (White participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.
At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable at Treatment Week 8 and at all subsequent assays (up to Treatment Week 24), will proceed to the 44-week follow-up.
At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up.</description>
        </group>
        <group group_id="B3">
          <title>Cohort I - 3. Boceprevir + PEG + RBV - 44 Weeks</title>
          <description>Cohort I (White participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
        </group>
        <group group_id="B4">
          <title>Cohort II - 1. Placebo + PEG + RBV</title>
          <description>Cohort II (Black participants) treated with PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
        </group>
        <group group_id="B5">
          <title>Cohort II - 2. Boceprevir + PEG + RBV - 24 Weeks (RGT)</title>
          <description>Cohort II (Black participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.
At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable at Treatment Week 8 and at all subsequent assays (up to Treatment Week 24), will proceed to the 44-week follow-up.
At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up.</description>
        </group>
        <group group_id="B6">
          <title>Cohort II - 3. Boceprevir + PEG + RBV - 44 Weeks</title>
          <description>Cohort II (Black participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="311"/>
            <count group_id="B2" value="316"/>
            <count group_id="B3" value="311"/>
            <count group_id="B4" value="52"/>
            <count group_id="B5" value="52"/>
            <count group_id="B6" value="55"/>
            <count group_id="B7" value="1097"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 40 and &lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="246"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="255"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="47"/>
                    <measurement group_id="B6" value="51"/>
                    <measurement group_id="B7" value="905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="441"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="188"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="33"/>
                    <measurement group_id="B7" value="656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sustained Virologic Response (SVR) Rate</title>
        <description>Previously untreated adults with CHC genotype 1 were treated with the assigned study medication. Participants who had undetectable plasma HCV-RNA at FW 24 had achieved SVR. SVR rate is the percent of participants achieving SVR.
HCV-RNA was detected by a nucleic acid amplification test and the limit of detection for this assay is 9.3 IU/mL.
If a participant was missing data at FW 24 after having had undetectable HCV-RNA at FW 12, the participant was to be considered to have SVR.</description>
        <time_frame>At Follow-up Week (FW) 24</time_frame>
        <population>Full analysis set (FAS). All randomized participants who received at least one dose of any study medication (PEG, RBV or boceprevir).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - 1. Placebo + PEG + RBV</title>
            <description>Cohort I (White participants) treated with PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O2">
            <title>Cohort I - 2. Boceprevir + PEG + RBV - 24 Weeks (RGT)</title>
            <description>Cohort I (White participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.
At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable at Treatment Week 8 and at all subsequent assays (up to Treatment Week 24), will proceed to the 44-week follow-up.
At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I - 3. Boceprevir + PEG + RBV - 44 Weeks</title>
            <description>Cohort I (White participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O4">
            <title>Cohort II - 1. Placebo + PEG + RBV</title>
            <description>Cohort II (Black participants) treated with PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O5">
            <title>Cohort II - 2. Boceprevir + PEG + RBV - 24 Weeks (RGT)</title>
            <description>Cohort II (Black participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.
At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable at Treatment Week 8 and at all subsequent assays (up to Treatment Week 24), will proceed to the 44-week follow-up.
At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O6">
            <title>Cohort II - 3. Boceprevir + PEG + RBV - 44 Weeks</title>
            <description>Cohort II (Black participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Virologic Response (SVR) Rate</title>
          <description>Previously untreated adults with CHC genotype 1 were treated with the assigned study medication. Participants who had undetectable plasma HCV-RNA at FW 24 had achieved SVR. SVR rate is the percent of participants achieving SVR.
HCV-RNA was detected by a nucleic acid amplification test and the limit of detection for this assay is 9.3 IU/mL.
If a participant was missing data at FW 24 after having had undetectable HCV-RNA at FW 12, the participant was to be considered to have SVR.</description>
          <population>Full analysis set (FAS). All randomized participants who received at least one dose of any study medication (PEG, RBV or boceprevir).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="316"/>
                <count group_id="O3" value="311"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2"/>
                    <measurement group_id="O2" value="66.8"/>
                    <measurement group_id="O3" value="68.5"/>
                    <measurement group_id="O4" value="23.1"/>
                    <measurement group_id="O5" value="42.3"/>
                    <measurement group_id="O6" value="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel Haenszel Chi-square test</method>
            <method_desc>Adjustments were made for for baseline stratification factors: viral load (&gt;400,000 vs. ≤400,000 IU/mL) and Genotype (1a vs 1b).</method_desc>
            <param_type>The difference in SVR</param_type>
            <param_value>26.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.1</ci_lower_limit>
            <ci_upper_limit>34.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel Haenszel Chi-square test</method>
            <method_desc>Adjustments were made for baseline stratification factors: viral load (&gt;400,000 vs. ≤400,000 IU/mL) and Genotype (1a vs 1b).</method_desc>
            <param_type>The difference in SVR</param_type>
            <param_value>28.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.8</ci_lower_limit>
            <ci_upper_limit>35.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0440</p_value>
            <method>Cochran-Mantel Haenszel Chi-square test</method>
            <method_desc>Adjustments were made for the baseline stratification factors: viral load (&gt;400,000 vs. ≤400,000 IU/mL) and Genotype (1a vs 1b).</method_desc>
            <param_type>The difference in SVR</param_type>
            <param_value>19.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.6</ci_lower_limit>
            <ci_upper_limit>36.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0035</p_value>
            <method>Cochran-Mantel Haenszel Chi-square</method>
            <method_desc>Adjustments were made for the baseline stratification factors: viral load (&gt;400,000 vs. ≤400,000 IU/mL) and Genotype (1a vs 1b).</method_desc>
            <param_type>The difference in SVR</param_type>
            <param_value>29.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.2</ci_lower_limit>
            <ci_upper_limit>47.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Virologic Response (SVR) Rate in Participants Treated With Study Drug (Boceprevir or Placebo)</title>
        <description>Previously untreated adults with CHC genotype 1 were treated with the assigned study medication. Participants who had undetectable plasma HCV-RNA at FW 24 had achieved SVR. SVR rate was the percentage of participants treated with at least one dose of boceprevir or placebo who had achieved SVR.
HCV-RNA in participant's plasma samples was detected by a nucleic acid amplification assay with a limit of detection of 9.3 IU/mL.
If a participant was missing data at FW 24 after having had undetectable HCV-RNA at FW 12, the participant was to be considered to have a SVR.</description>
        <time_frame>At FW 24</time_frame>
        <population>Modified intent-to-treat set (mITT). All randomized participants who received at least one dose of boceprevir or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - 1. Placebo + PEG + RBV</title>
            <description>Cohort I (White participants) treated with PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O2">
            <title>Cohort I - 2. Boceprevir + PEG + RBV - 24 Weeks (RGT)</title>
            <description>Cohort I (White participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.
At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable at Treatment Week 8 and at all subsequent assays (up to Treatment Week 24), will proceed to the 44-week follow-up.
At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I - 3. Boceprevir + PEG + RBV - 44 Weeks</title>
            <description>Cohort I (White participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O4">
            <title>Cohort II - 1. Placebo + PEG + RBV</title>
            <description>Cohort II (Black participants) treated with PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O5">
            <title>Cohort II - 2. Boceprevir + PEG + RBV - 24 Weeks (RGT)</title>
            <description>Cohort II (Black participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.
At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable at Treatment Week 8 and at all subsequent assays (up to Treatment Week 24), will proceed to the 44-week follow-up.
At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O6">
            <title>Cohort II - 3. Boceprevir + PEG + RBV - 44 Weeks</title>
            <description>Cohort II (Black participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Virologic Response (SVR) Rate in Participants Treated With Study Drug (Boceprevir or Placebo)</title>
          <description>Previously untreated adults with CHC genotype 1 were treated with the assigned study medication. Participants who had undetectable plasma HCV-RNA at FW 24 had achieved SVR. SVR rate was the percentage of participants treated with at least one dose of boceprevir or placebo who had achieved SVR.
HCV-RNA in participant's plasma samples was detected by a nucleic acid amplification assay with a limit of detection of 9.3 IU/mL.
If a participant was missing data at FW 24 after having had undetectable HCV-RNA at FW 12, the participant was to be considered to have a SVR.</description>
          <population>Modified intent-to-treat set (mITT). All randomized participants who received at least one dose of boceprevir or placebo.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="303"/>
                <count group_id="O3" value="299"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1"/>
                    <measurement group_id="O2" value="69.6"/>
                    <measurement group_id="O3" value="71.2"/>
                    <measurement group_id="O4" value="25.5"/>
                    <measurement group_id="O5" value="46.8"/>
                    <measurement group_id="O6" value="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel Haenszel Chi-square</method>
            <method_desc>Adjustments were made for the baseline stratification factors: viral load (&gt;400,000 vs. ≤400,000 IU/mL) and Genotype (1a vs 1b).</method_desc>
            <param_type>The difference in SVR rates</param_type>
            <param_value>27.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.2</ci_lower_limit>
            <ci_upper_limit>35.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel Haenszel Chi-square</method>
            <method_desc>Adjustments were made for the baseline stratification factors: viral load (&gt;400,000 vs. ≤400,000 IU/mL) and Genotype (1a vs 1b).</method_desc>
            <param_type>The difference in SVR rates</param_type>
            <param_value>29.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.5</ci_lower_limit>
            <ci_upper_limit>36.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0366</p_value>
            <method>Cochran-Mantel Haenszel Chi-square test</method>
            <method_desc>Adjustments were made for the baseline stratification factors: viral load (&gt;400,000 vs. ≤400,000 IU/mL) and Genotype (1a vs 1b).</method_desc>
            <param_type>The difference in SVR</param_type>
            <param_value>21.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.3</ci_lower_limit>
            <ci_upper_limit>40.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0107</p_value>
            <method>Cochran-Mantel Haenszel Chi-square</method>
            <method_desc>Adjustments were made for the baseline stratification factors: viral load (&gt;400,000 vs. ≤400,000 IU/mL) and Genotype (1a vs 1b).</method_desc>
            <param_type>The difference in SVR</param_type>
            <param_value>27.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.0</ci_lower_limit>
            <ci_upper_limit>45.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Undetectable HCV-RNA at Follow-up Week 12 and at 72 Weeks After Randomization.</title>
        <description>Previously untreated adults with CHC genotype 1 were treated with the assigned study medication. The number of participants who had undetectable plasma HCV-RNA at FW 12, and 72 weeks after randomization are reported.
HCV-RNA was detected by a nucleic acid amplification test and the limit of detection for this assay is 9.3 IU/mL.</description>
        <time_frame>At FW 12 and at 72 weeks after randomization</time_frame>
        <population>Full analysis set (FAS). All randomized participants who received at least one dose of any study medication (PEG, RBV or boceprevir).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - 1. Placebo + PEG + RBV</title>
            <description>Cohort I (White participants) treated with PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O2">
            <title>Cohort I - 2. Boceprevir + PEG + RBV - 24 Weeks (RGT)</title>
            <description>Cohort I (White participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.
At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable at Treatment Week 8 and at all subsequent assays (up to Treatment Week 24), will proceed to the 44-week follow-up.
At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I - 3. Boceprevir + PEG + RBV - 44 Weeks</title>
            <description>Cohort I (White participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O4">
            <title>Cohort II - 1. Placebo + PEG + RBV</title>
            <description>Cohort II (Black participants) treated with PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O5">
            <title>Cohort II - 2. Boceprevir + PEG + RBV - 24 Weeks (RGT)</title>
            <description>Cohort II (Black participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.
At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable at Treatment Week 8 and at all subsequent assays (up to Treatment Week 24), will proceed to the 44-week follow-up.
At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O6">
            <title>Cohort II - 3. Boceprevir + PEG + RBV - 44 Weeks</title>
            <description>Cohort II (Black participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Undetectable HCV-RNA at Follow-up Week 12 and at 72 Weeks After Randomization.</title>
          <description>Previously untreated adults with CHC genotype 1 were treated with the assigned study medication. The number of participants who had undetectable plasma HCV-RNA at FW 12, and 72 weeks after randomization are reported.
HCV-RNA was detected by a nucleic acid amplification test and the limit of detection for this assay is 9.3 IU/mL.</description>
          <population>Full analysis set (FAS). All randomized participants who received at least one dose of any study medication (PEG, RBV or boceprevir).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="316"/>
                <count group_id="O3" value="311"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At follow-up week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="209"/>
                    <measurement group_id="O3" value="209"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 weeks after randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="194"/>
                    <measurement group_id="O3" value="205"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Early Virologic Response (Undetectable HCV-RNA at Treatment Week 2, 4, 8, 12, 16, or 20)</title>
        <description>Early virologic response was defined as undetectable HCV-RNA at in participants by treatment week 2, 4, 8, 12, 16, or 20.
HCV-RNA in participant's plasma samples was detected by a nucleic acid amplification assay with a limit of detection of 9.3 IU/mL.</description>
        <time_frame>At Treatment Week 2, 4, 8, 12, 16, or 20</time_frame>
        <population>Full analysis set (FAS). All randomized participants who received at least one dose of any study medication (PEG, RBV or boceprevir).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - 1. Placebo + PEG + RBV</title>
            <description>Cohort I (White participants) treated with PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O2">
            <title>Cohort I - 2. Boceprevir + PEG + RBV - 24 Weeks (RGT)</title>
            <description>Cohort I (White participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.
At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable at Treatment Week 8 and at all subsequent assays (up to Treatment Week 24), will proceed to the 44-week follow-up.
At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I - 3. Boceprevir + PEG + RBV - 44 Weeks</title>
            <description>Cohort I (White participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O4">
            <title>Cohort II - 1. Placebo + PEG + RBV</title>
            <description>Cohort II (Black participants) treated with PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O5">
            <title>Cohort II - 2. Boceprevir + PEG + RBV - 24 Weeks (RGT)</title>
            <description>Cohort II (Black participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.
At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable at Treatment Week 8 and at all subsequent assays (up to Treatment Week 24), will proceed to the 44-week follow-up.
At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O6">
            <title>Cohort II - 3. Boceprevir + PEG + RBV - 44 Weeks</title>
            <description>Cohort II (Black participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Early Virologic Response (Undetectable HCV-RNA at Treatment Week 2, 4, 8, 12, 16, or 20)</title>
          <description>Early virologic response was defined as undetectable HCV-RNA at in participants by treatment week 2, 4, 8, 12, 16, or 20.
HCV-RNA in participant's plasma samples was detected by a nucleic acid amplification assay with a limit of detection of 9.3 IU/mL.</description>
          <population>Full analysis set (FAS). All randomized participants who received at least one dose of any study medication (PEG, RBV or boceprevir).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="316"/>
                <count group_id="O3" value="311"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="190"/>
                    <measurement group_id="O3" value="182"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="237"/>
                    <measurement group_id="O3" value="231"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="231"/>
                    <measurement group_id="O3" value="237"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="231"/>
                    <measurement group_id="O3" value="231"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="27"/>
                    <measurement group_id="O6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Early Virologic Response (Undetectable HCV-RNA at Treatment Week 4, 8, 12, 16, or 20) Who Achieved SVR</title>
        <description>Participants with early virologic response were those who had undetectable HCV-RNA by treatment week 4, 8, 12, 16, or 20. Participants who had undetectable plasma HCV-RNA at FW 24 had SVR. The number of participants with early virologic response that also achieved SVR is reported.
HCV-RNA in participant's plasma samples was detected by a nucleic acid amplification assay with a limit of detection of 9.3 IU/mL.</description>
        <time_frame>At Treatment Week 4, 8, 12, 16, 20</time_frame>
        <population>Participants that had undetectable HCV RNA for the treatment weeks 4, 8, 12, 16, and 20.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - 1. Placebo + PEG + RBV</title>
            <description>Cohort I (White participants) treated with PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O2">
            <title>Cohort I - 2. Boceprevir + PEG + RBV - 24 Weeks (RGT)</title>
            <description>Cohort I (White participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.
At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable at Treatment Week 8 and at all subsequent assays (up to Treatment Week 24), will proceed to the 44-week follow-up.
At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I - 3. Boceprevir + PEG + RBV - 44 Weeks</title>
            <description>Cohort I (White participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O4">
            <title>Cohort II - 1. Placebo + PEG + RBV</title>
            <description>Cohort II (Black participants) treated with PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O5">
            <title>Cohort II - 2. Boceprevir + PEG + RBV - 24 Weeks (RGT)</title>
            <description>Cohort II (Black participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.
At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable at Treatment Week 8 and at all subsequent assays (up to Treatment Week 24), will proceed to the 44-week follow-up.
At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up.</description>
          </group>
          <group group_id="O6">
            <title>Cohort II - 3. Boceprevir + PEG + RBV - 44 Weeks</title>
            <description>Cohort II (Black participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Early Virologic Response (Undetectable HCV-RNA at Treatment Week 4, 8, 12, 16, or 20) Who Achieved SVR</title>
          <description>Participants with early virologic response were those who had undetectable HCV-RNA by treatment week 4, 8, 12, 16, or 20. Participants who had undetectable plasma HCV-RNA at FW 24 had SVR. The number of participants with early virologic response that also achieved SVR is reported.
HCV-RNA in participant's plasma samples was detected by a nucleic acid amplification assay with a limit of detection of 9.3 IU/mL.</description>
          <population>Participants that had undetectable HCV RNA for the treatment weeks 4, 8, 12, 16, and 20.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="316"/>
                <count group_id="O3" value="311"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment week 4 (n=28, 18, 20, 2, 1, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment week 8 (n=56, 190, 182, 4, 18, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="170"/>
                    <measurement group_id="O3" value="166"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment week 12 (n=108, 237, 231, 10, 25, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="205"/>
                    <measurement group_id="O3" value="204"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment week 16 (n=138, 231, 237, 15, 26, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="205"/>
                    <measurement group_id="O3" value="210"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment week 20 (n=157, 231, 231, 15, 27, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="201"/>
                    <measurement group_id="O3" value="208"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PEG + RBV</title>
          <description>Cohort I (White participants) and Cohort II (Black participants) treated with PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
        </group>
        <group group_id="E2">
          <title>BOCEPREVIR + PEG + RBV - 24 WEEKS</title>
          <description>Cohort I (White participants) and Cohort II (Black participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.
At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable at Treatment Week 8 and at all subsequent assays (up to Treatment Week 24), will proceed to the 44-week follow-up.
At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up.</description>
        </group>
        <group group_id="E3">
          <title>BOCEPRIVIR + PEG + RBV - 44 WEEKS</title>
          <description>Cohort I (White participants) and Cohort II (Black participants) treated with PEG 1.5 μg/kg + RBV (WBD) for 4 weeks followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="368"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>APLASIA PURE RED CELL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>HYPERTROPHIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>DEAFNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>OPTIC NEUROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>PAPILLOEDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>COLONIC POLYP</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>MALLORY-WEISS SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS OBSTRUCTIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>SARCOIDOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>ATYPICAL MYCOBACTERIAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS INFECTIOUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>EPIGLOTTITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>INFECTED BITES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>INJECTION SITE INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>PERIRECTAL ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PNEUMOCOCCAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>SCROTAL ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>TRACHEOBRONCHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACCIDENTAL OVERDOSE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>ALCOHOL POISONING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>SPINAL FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>TRANSFUSION REACTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>FLANK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>GROIN PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BLADDER CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>MOTOR NEURONE DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASTICITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>AFFECTIVE DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>ALCOHOL ABUSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>BIPOLAR I DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>COMPLETED SUICIDE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>DRUG ABUSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>DRUG DEPENDENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>INTENTIONAL SELF-INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>PERSONALITY DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>PSYCHIATRIC DECOMPENSATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>GLOMERULONEPHRITIS MINIMAL LESION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>RENAL TUBULAR NECROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>SCROTAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>PLEURAL FIBROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>RASH ERYTHEMATOUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>ALCOHOL USE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>PHYSICAL ASSAULT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTECTOMY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>LARYNGEAL OPERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>SKIN NEOPLASM EXCISION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ACCELERATED HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>ARTERIAL THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="353" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="365" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="363" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="188" subjects_affected="107" subjects_at_risk="363"/>
                <counts group_id="E2" events="292" subjects_affected="182" subjects_at_risk="368"/>
                <counts group_id="E3" events="352" subjects_affected="179" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="81" subjects_affected="33" subjects_at_risk="363"/>
                <counts group_id="E2" events="83" subjects_affected="31" subjects_at_risk="368"/>
                <counts group_id="E3" events="126" subjects_affected="45" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="208" subjects_affected="77" subjects_at_risk="363"/>
                <counts group_id="E2" events="216" subjects_affected="91" subjects_at_risk="368"/>
                <counts group_id="E3" events="257" subjects_affected="93" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="16" subjects_affected="7" subjects_at_risk="363"/>
                <counts group_id="E2" events="50" subjects_affected="16" subjects_at_risk="368"/>
                <counts group_id="E3" events="38" subjects_affected="19" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>DRY EYE</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="363"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="368"/>
                <counts group_id="E3" events="24" subjects_affected="22" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="363"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="368"/>
                <counts group_id="E3" events="25" subjects_affected="22" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="30" subjects_affected="20" subjects_at_risk="363"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="368"/>
                <counts group_id="E3" events="28" subjects_affected="23" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="40" subjects_affected="32" subjects_at_risk="363"/>
                <counts group_id="E2" events="41" subjects_affected="30" subjects_at_risk="368"/>
                <counts group_id="E3" events="54" subjects_affected="44" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="34" subjects_affected="32" subjects_at_risk="363"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="368"/>
                <counts group_id="E3" events="34" subjects_affected="32" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="103" subjects_affected="79" subjects_at_risk="363"/>
                <counts group_id="E2" events="104" subjects_affected="80" subjects_at_risk="368"/>
                <counts group_id="E3" events="125" subjects_affected="100" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="45" subjects_affected="40" subjects_at_risk="363"/>
                <counts group_id="E2" events="42" subjects_affected="39" subjects_at_risk="368"/>
                <counts group_id="E3" events="51" subjects_affected="43" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="39" subjects_affected="32" subjects_at_risk="363"/>
                <counts group_id="E2" events="35" subjects_affected="29" subjects_at_risk="368"/>
                <counts group_id="E3" events="40" subjects_affected="33" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="363"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="368"/>
                <counts group_id="E3" events="22" subjects_affected="20" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="199" subjects_affected="153" subjects_at_risk="363"/>
                <counts group_id="E2" events="231" subjects_affected="175" subjects_at_risk="368"/>
                <counts group_id="E3" events="212" subjects_affected="159" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="70" subjects_affected="57" subjects_at_risk="363"/>
                <counts group_id="E2" events="99" subjects_affected="75" subjects_at_risk="368"/>
                <counts group_id="E3" events="90" subjects_affected="70" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="129" subjects_affected="70" subjects_at_risk="363"/>
                <counts group_id="E2" events="86" subjects_affected="55" subjects_at_risk="368"/>
                <counts group_id="E3" events="132" subjects_affected="70" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="114" subjects_affected="102" subjects_at_risk="363"/>
                <counts group_id="E2" events="156" subjects_affected="134" subjects_at_risk="368"/>
                <counts group_id="E3" events="139" subjects_affected="121" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="279" subjects_affected="217" subjects_at_risk="363"/>
                <counts group_id="E2" events="250" subjects_affected="196" subjects_at_risk="368"/>
                <counts group_id="E3" events="290" subjects_affected="209" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="160" subjects_affected="93" subjects_at_risk="363"/>
                <counts group_id="E2" events="113" subjects_affected="91" subjects_at_risk="368"/>
                <counts group_id="E3" events="102" subjects_affected="83" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" events="55" subjects_affected="47" subjects_at_risk="363"/>
                <counts group_id="E2" events="48" subjects_affected="46" subjects_at_risk="368"/>
                <counts group_id="E3" events="38" subjects_affected="37" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>INJECTION SITE REACTION</sub_title>
                <counts group_id="E1" events="46" subjects_affected="44" subjects_at_risk="363"/>
                <counts group_id="E2" events="46" subjects_affected="45" subjects_at_risk="368"/>
                <counts group_id="E3" events="39" subjects_affected="39" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" events="106" subjects_affected="86" subjects_at_risk="363"/>
                <counts group_id="E2" events="104" subjects_affected="81" subjects_at_risk="368"/>
                <counts group_id="E3" events="111" subjects_affected="83" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="36" subjects_affected="34" subjects_at_risk="363"/>
                <counts group_id="E2" events="43" subjects_affected="41" subjects_at_risk="368"/>
                <counts group_id="E3" events="41" subjects_affected="37" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="196" subjects_affected="120" subjects_at_risk="363"/>
                <counts group_id="E2" events="180" subjects_affected="123" subjects_at_risk="368"/>
                <counts group_id="E3" events="218" subjects_affected="117" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="363"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="368"/>
                <counts group_id="E3" events="22" subjects_affected="19" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="54" subjects_affected="46" subjects_at_risk="363"/>
                <counts group_id="E2" events="50" subjects_affected="43" subjects_at_risk="368"/>
                <counts group_id="E3" events="64" subjects_affected="52" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="101" subjects_affected="90" subjects_at_risk="363"/>
                <counts group_id="E2" events="107" subjects_affected="97" subjects_at_risk="368"/>
                <counts group_id="E3" events="98" subjects_affected="89" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="84" subjects_affected="66" subjects_at_risk="363"/>
                <counts group_id="E2" events="87" subjects_affected="69" subjects_at_risk="368"/>
                <counts group_id="E3" events="103" subjects_affected="72" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="45" subjects_affected="40" subjects_at_risk="363"/>
                <counts group_id="E2" events="33" subjects_affected="30" subjects_at_risk="368"/>
                <counts group_id="E3" events="45" subjects_affected="40" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="363"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="368"/>
                <counts group_id="E3" events="20" subjects_affected="18" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="125" subjects_affected="94" subjects_at_risk="363"/>
                <counts group_id="E2" events="98" subjects_affected="78" subjects_at_risk="368"/>
                <counts group_id="E3" events="120" subjects_affected="92" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="363"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="368"/>
                <counts group_id="E3" events="24" subjects_affected="21" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DISTURBANCE IN ATTENTION</sub_title>
                <counts group_id="E1" events="30" subjects_affected="27" subjects_at_risk="363"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="368"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="74" subjects_affected="59" subjects_at_risk="363"/>
                <counts group_id="E2" events="97" subjects_affected="80" subjects_at_risk="368"/>
                <counts group_id="E3" events="70" subjects_affected="66" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" events="68" subjects_affected="64" subjects_at_risk="363"/>
                <counts group_id="E2" events="143" subjects_affected="137" subjects_at_risk="368"/>
                <counts group_id="E3" events="164" subjects_affected="156" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="264" subjects_affected="153" subjects_at_risk="363"/>
                <counts group_id="E2" events="233" subjects_affected="168" subjects_at_risk="368"/>
                <counts group_id="E3" events="311" subjects_affected="167" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>MEMORY IMPAIRMENT</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="363"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="368"/>
                <counts group_id="E3" events="28" subjects_affected="24" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" events="32" subjects_affected="13" subjects_at_risk="363"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="368"/>
                <counts group_id="E3" events="23" subjects_affected="19" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="49" subjects_affected="42" subjects_at_risk="363"/>
                <counts group_id="E2" events="57" subjects_affected="50" subjects_at_risk="368"/>
                <counts group_id="E3" events="65" subjects_affected="48" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="86" subjects_affected="78" subjects_at_risk="363"/>
                <counts group_id="E2" events="103" subjects_affected="82" subjects_at_risk="368"/>
                <counts group_id="E3" events="85" subjects_affected="69" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="137" subjects_affected="118" subjects_at_risk="363"/>
                <counts group_id="E2" events="145" subjects_affected="117" subjects_at_risk="368"/>
                <counts group_id="E3" events="141" subjects_affected="122" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>MOOD SWINGS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="363"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="368"/>
                <counts group_id="E3" events="21" subjects_affected="19" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="87" subjects_affected="76" subjects_at_risk="363"/>
                <counts group_id="E2" events="69" subjects_affected="56" subjects_at_risk="368"/>
                <counts group_id="E3" events="100" subjects_affected="74" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="66" subjects_affected="59" subjects_at_risk="363"/>
                <counts group_id="E2" events="87" subjects_affected="68" subjects_at_risk="368"/>
                <counts group_id="E3" events="94" subjects_affected="84" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" events="33" subjects_affected="30" subjects_at_risk="363"/>
                <counts group_id="E2" events="44" subjects_affected="42" subjects_at_risk="368"/>
                <counts group_id="E3" events="39" subjects_affected="31" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="363"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="368"/>
                <counts group_id="E3" events="21" subjects_affected="21" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="363"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="368"/>
                <counts group_id="E3" events="34" subjects_affected="33" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="105" subjects_affected="99" subjects_at_risk="363"/>
                <counts group_id="E2" events="82" subjects_affected="75" subjects_at_risk="368"/>
                <counts group_id="E3" events="109" subjects_affected="104" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="77" subjects_affected="66" subjects_at_risk="363"/>
                <counts group_id="E2" events="72" subjects_affected="67" subjects_at_risk="368"/>
                <counts group_id="E3" events="98" subjects_affected="86" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="130" subjects_affected="98" subjects_at_risk="363"/>
                <counts group_id="E2" events="101" subjects_affected="87" subjects_at_risk="368"/>
                <counts group_id="E3" events="138" subjects_affected="94" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="124" subjects_affected="83" subjects_at_risk="363"/>
                <counts group_id="E2" events="111" subjects_affected="93" subjects_at_risk="368"/>
                <counts group_id="E3" events="119" subjects_affected="88" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In this multicenter trial, initially, the investigator may only publish study results together with the other sites, unless specific written permission is obtained in advance from the sponsor.
The disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a 45 day period from the time submitted to the sponsor for review.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

